1. Home
  2. TJX vs VRTX Comparison

TJX vs VRTX Comparison

Compare TJX & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TJX Companies Inc. (The)

TJX

TJX Companies Inc. (The)

HOLD

Current Price

$131.73

Market Cap

146.6B

ML Signal

HOLD

Logo Vertex Pharmaceuticals Incorporated

VRTX

Vertex Pharmaceuticals Incorporated

HOLD

Current Price

$523.86

Market Cap

128.8B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
TJX
VRTX
Founded
1962
1989
Country
United States
United States
Employees
N/A
N/A
Industry
Clothing/Shoe/Accessory Stores
EDP Services
Sector
Consumer Discretionary
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
146.6B
128.8B
IPO Year
1994
2006

Fundamental Metrics

Financial Performance
Metric
TJX
VRTX
Price
$131.73
$523.86
Analyst Decision
Strong Buy
Buy
Analyst Count
16
29
Target Price
$169.00
★ $539.69
AVG Volume (30 Days)
★ 6.1M
876.4K
Earning Date
05-20-2026
05-04-2026
Dividend Yield
★ 1.23%
N/A
EPS Growth
14.32
★ 836.54
EPS
2.55
★ 8.33
Revenue
★ $29,078,407,000.00
$2,488,652,000.00
Revenue This Year
$6.75
$10.79
Revenue Next Year
$5.81
$10.47
P/E Ratio
★ $51.09
$63.35
Revenue Growth
6.04
★ 46.20
52 Week Low
$122.81
$392.82
52 Week High
$170.00
$560.25

Technical Indicators

Market Signals
Indicator
TJX
VRTX
Relative Strength Index (RSI) 46.95 50.98
Support Level $122.81 $423.93
Resistance Level $162.20 $533.67
Average True Range (ATR) 2.73 11.06
MACD 1.42 -0.28
Stochastic Oscillator 94.77 79.50

Price Performance

Historical Comparison
TJX
VRTX

About TJX TJX Companies Inc. (The)

Founded in 1987, TJX Companies is the world's largest off-price apparel and home fashions retailer, operating more than 5,000 stores across nine countries. In fiscal 2026, the company generated roughly $60 billion in sales. TJX operates through four segments: Marmaxx (61% of sales), HomeGoods (17%), TJX Canada (9%), and TJX international (13%). Its off-price model emphasizes branded merchandise at meaningful discounts, driving high traffic and rapid inventory turnover.

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Share on Social Networks: